MX2007003533A - Metodos de tratar linfomas cd30 positivas. - Google Patents

Metodos de tratar linfomas cd30 positivas.

Info

Publication number
MX2007003533A
MX2007003533A MX2007003533A MX2007003533A MX2007003533A MX 2007003533 A MX2007003533 A MX 2007003533A MX 2007003533 A MX2007003533 A MX 2007003533A MX 2007003533 A MX2007003533 A MX 2007003533A MX 2007003533 A MX2007003533 A MX 2007003533A
Authority
MX
Mexico
Prior art keywords
methods
treating
positive lymphomas
lymphomas
positive
Prior art date
Application number
MX2007003533A
Other languages
English (en)
Spanish (es)
Inventor
Tibor Keler
Elke Pogge Von Strandmann
Andreas Engert
Peter Borchmann
Boris Boell
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of MX2007003533A publication Critical patent/MX2007003533A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2007003533A 2004-10-01 2005-09-30 Metodos de tratar linfomas cd30 positivas. MX2007003533A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61528404P 2004-10-01 2004-10-01
PCT/US2005/035477 WO2006039644A2 (en) 2004-10-01 2005-09-30 Methods of treating cd30 positive lymphomas

Publications (1)

Publication Number Publication Date
MX2007003533A true MX2007003533A (es) 2007-05-23

Family

ID=35929979

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003533A MX2007003533A (es) 2004-10-01 2005-09-30 Metodos de tratar linfomas cd30 positivas.

Country Status (13)

Country Link
US (1) US7790160B2 (enExample)
EP (1) EP1802345A2 (enExample)
JP (1) JP2008514730A (enExample)
KR (1) KR20070083899A (enExample)
CN (1) CN101056655A (enExample)
AU (1) AU2005292227A1 (enExample)
BR (1) BRPI0516727A (enExample)
CA (1) CA2582016A1 (enExample)
IL (1) IL182260A0 (enExample)
MX (1) MX2007003533A (enExample)
NO (1) NO20071714L (enExample)
WO (1) WO2006039644A2 (enExample)
ZA (1) ZA200703154B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2471702C (en) 2002-01-09 2013-03-19 Medarex, Inc. Human monoclonal antibodies against cd30
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP1802345A2 (en) 2004-10-01 2007-07-04 Medarex, Inc. Methods of treating cd30 positive lymphomas
NZ560209A (en) * 2005-02-18 2009-04-30 Medarex Inc Monoclonal antibodies against CD30 lacking in fucosyl residues
WO2006116246A2 (en) * 2005-04-25 2006-11-02 Medarex, Inc. Method of treating cd30 positive lymphomas
US20090175886A1 (en) * 2006-01-17 2009-07-09 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
EP2155231B1 (en) * 2007-04-10 2012-08-08 The Johns Hopkins University Imaging and therapy of virus-associated tumors
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
CN104254778A (zh) 2012-02-10 2014-12-31 西雅图遗传学公司 Cd30+癌症的检测和治疗
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
ES2728578T3 (es) 2013-09-20 2019-10-25 Bristol Myers Squibb Co Combinación de anticuerpos anti-LAG-3 y anticuerpos anti-PD-1 para tratar tumores
TWI660739B (zh) * 2013-10-25 2019-06-01 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
JP6525474B2 (ja) * 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
KR20240110004A (ko) 2014-03-14 2024-07-12 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
EP3167292A4 (en) * 2014-07-11 2018-05-23 Expression Pathology, Inc. Srm/mrm assay for the tumor necrosis factor receptor superfamily member 8 (cd30) protein
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN109562084A (zh) * 2016-08-04 2019-04-02 米伦纽姆医药公司 蛋白酶体抑制剂和抗cd30抗体的组合
CN106854245A (zh) * 2016-12-28 2017-06-16 无锡傲锐东源生物科技有限公司 抗cd30蛋白单克隆抗体及其用途
CN110720039A (zh) 2017-05-30 2020-01-21 百时美施贵宝公司 Lag-3阳性肿瘤的治疗
CN118356488A (zh) 2017-05-30 2024-07-19 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
EP4301783A4 (en) 2021-03-01 2025-04-23 NantBio, Inc. Anti-cd30 monoclonal antibodies and chimeric antigen receptors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
WO1991007437A2 (en) 1989-11-20 1991-05-30 Parker, David, L. Improved cd-30 antibodies and fragments thereof
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DE4200043A1 (de) 1991-11-11 1993-05-13 Stein Harald Prof Dr Lymphoides cd30-antigen (ki-1), dessen protein- und die zugehoerige nucleotidsequenz, seine herstellung sowie mittel zur diagnose und untersuchung von tumoren
DK0615451T3 (da) * 1992-05-26 2006-04-24 Immunex Corp Hidtil ukendt cytokin der binder til CD30
WO1994004189A1 (en) 1992-08-25 1994-03-03 Medac Gesellschaft Fur Klinische Spezialpräparate Mbh Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
DE4337197C1 (de) * 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US6033876A (en) * 1995-01-18 2000-03-07 Boehringer Mannheim Gmbh Anti-CD30 antibodies preventing proteolytic cleavage and release of membrane-bound CD30 antigen
DE19543039C1 (de) 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
WO1999040187A1 (de) 1998-02-06 1999-08-12 Hinrich Abken Nukleinsäuren zur modulation zellulärer aktivierung
DE19937264A1 (de) 1999-08-06 2001-02-15 Deutsches Krebsforsch F¶v¶-Antikörper-Konstrukte
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
AU2001285286A1 (en) 2000-08-29 2002-03-13 Noveon Ip Holdings Corp. Hydrogels containing substances
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
EP1443961B1 (en) * 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
CA2471702C (en) * 2002-01-09 2013-03-19 Medarex, Inc. Human monoclonal antibodies against cd30
CA2492671C (en) 2002-03-22 2012-04-17 Aprogen, Inc. Humanized antibody and process for preparing same
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
EP1802345A2 (en) 2004-10-01 2007-07-04 Medarex, Inc. Methods of treating cd30 positive lymphomas
NZ560209A (en) 2005-02-18 2009-04-30 Medarex Inc Monoclonal antibodies against CD30 lacking in fucosyl residues

Also Published As

Publication number Publication date
EP1802345A2 (en) 2007-07-04
CN101056655A (zh) 2007-10-17
CA2582016A1 (en) 2006-04-13
US20060177442A1 (en) 2006-08-10
IL182260A0 (en) 2007-07-24
ZA200703154B (en) 2008-09-25
US7790160B2 (en) 2010-09-07
NO20071714L (no) 2007-06-28
KR20070083899A (ko) 2007-08-24
WO2006039644A3 (en) 2006-08-10
WO2006039644A2 (en) 2006-04-13
JP2008514730A (ja) 2008-05-08
AU2005292227A1 (en) 2006-04-13
BRPI0516727A (pt) 2008-09-16

Similar Documents

Publication Publication Date Title
MX2007003533A (es) Metodos de tratar linfomas cd30 positivas.
NL301145I1 (enExample)
TW200740803A (en) Heterocyclic derivatives as modulators of ion channels
MY169308A (en) Treatment of tnf? related disorders
MY160041A (en) Compositions and methods for treating parasitic infections
PH12014500053A1 (en) Proteasome inhibitors
AU2003291356A8 (en) Methods and compositions for treating cancer using proteasome inhibitors
NO20070052L (no) Fremgangsmate for behandling av multippel sklerose
IL187382A0 (en) Bicyclic derivatives as modulators of ion channels
TW200637574A (en) Treatment method
EP1628623A4 (en) METHOD FOR THE TREATMENT OF DISEASES WITH HSP90-INHIBITING AGENTS COMBINED WITH ENZYME-INHIBITORS
IL184047A0 (en) Methods and compositions for treating amyloid-related diseases
SG148217A1 (en) Method for treating adamts-5-associated disease
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
IL182061A0 (en) Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus
TW200744568A (en) Epinephrine dosing regimens
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
ATE435214T1 (de) Als ionenkanalmodulatoren geeignete chinazoline
MX2010005307A (es) Derivados heterociclicos como moduladores de canales de iones.
MY160406A (en) Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent
TW200508233A (en) Chk-1 inhibitors
MX2009003022A (es) Composiciones y metodos para tratar picaduras de medusa.
SG136953A1 (en) Aqueous cleaning composition and method for using same
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств

Legal Events

Date Code Title Description
FA Abandonment or withdrawal